Search reports.
Major Tranquilizers Market Share, Growth, Opportunities 2031
Get free sample report Request for Customiztion Buy Now

Major Tranquilizers Market Share, Growth, Opportunities 2031

Segments - Major Tranquilizers Market by Types (First Generation, Second Generation, and Third Generation), Applications (Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031

https://growthmarketreports.com/raksha
Author : Raksha Sharma
https://growthmarketreports.com/Vaibhav
Fact-checked by : V. Chandola
https://growthmarketreports.com/Vishal
Editor : Vishal Golekar

Upcoming | Report ID :HC-792 | 4.4 Rating | 68 Reviews | 150 Pages | Format : PDF Excel PPT

Report Description


The global major tranquilizer market size was valued at USD 2.14 billion in 2022 and is projected to reach USD 2.89 billion by 2031 at a CAGR of 3.4% during the forecast period 2023-2031. The growth of the market is attributed to its drivers such as rising health issues in people.

Tranquilizer reduces mental tension, relieve anxiety, and result in outlook without producing any marked degree of hypnosis or sedation. Tranquilizers play a vital role in psychological disorder treatments. During these postmodern eras mental illness is common in many people because of the work pressure, tension, and anxiety.

Major Tranquilizers Market Outlook

The conventional antipsychotic was first developed in 1950s and was widely prescribed for the treatment of severe mental disorders. Thorazine (chlorpromazine) and Haldol (haloperidol) were the most commonly used typical antipsychotics. Atypical antipsychotics were approved in the 1990s for treating various psychiatric disorders.

These drugs were effective as compared to typical antipsychotics. In the fourth coming years more effective drugs may be launched in the market. The drug needs to be given under the supervision of expert, the patient can even loose, he’s or her lives if not given in correct measure or amount.

  • Increase in mental illness is projected to drive the the market.

  • Increasing geriatric population may increase the number of patients suffering from psychiatric disorders; this in turn is estimated to boost the market.

  • R&D investment and technological advancement for new products innovations is anticipated to create lucrative opportunities for the market players.

Scope of the Report

The report on the global tranquilizer market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Major Tranquilizers Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2022

Historic Data

2016–2021

Forecast Period

2023–2031

Segmentation

Types (First Generation, Second Generation, and Third Generation) and Applications (Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia, and Others)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Johnson & Johnson, Pfizer, Eli Lilly, Bristol-Myers Squibb, AstraZeneca, GSK, and Allergan

Market Segment Insights:

The first generation segment is estimated to expand at a rapid pace

Based on type, the global major tranquilizer market is segmented as first, second, and third generation. The first generation segment is projected to expand at a CAGR of 4% during the forecast period. Market growth is attributed to rising depression due to changing lifestyle and increasing number of mental hospitals. First generation drugs are used primarily for the treatment of schizophrenia and related psychotic disorder. The exact mechanism of action of antipsychotic drugs is unknown.

Second-generation drugs generally have lower risk of extrapyramidal side effects and tardive dyskinesia compared with first-generation. First- and second-generation antipsychotic drugs are more comparable in their clinical efficacy, with the exception of clozapine.

Major Tranquilizers Market Types

The bipolar disorder segment is estimated to expand at a CAGR of 5.2% during the forecast period

On the basis of applications, the global major tranquilizer market is fragmented into schizophrenia, bipolar disorder, unipolar depression, dementia, and others. The bipolar segment is anticipated to hold a major market share. Growth of the market is estimated to rising prevalence of mental illness and rising product launches. This kind of treatment should be done under supervision of expert and in proper measure. Medicine gives temporary relief to the medical condition.

Major Tranquilizers Market End User

The market in North America is projected to hold a major market share

In terms of regions, the global major tranquilizer market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market in North America is subjected to hold major share in the global market during the forecast period. According to food and drug administration (FDA), over 60 million people receive prescriptions for tranquilizers every year. One in five adults is living with some or the other mental illness.

Countries in Asia Pacific such as China, Japan, and Australia exhibit significant growth prospects in terms of rapid acceptance of novel molecules as well as the extensive use of generics. This region has a large number of patients suffering from psychological distress, cancer, AIDS, and other chronic disorders which is estimated to propel the market.

Major Tranquilizers Market Region

Segments

The global major tranquilizers market is segmented on the basis of

Types

  • First Generation
  • Second Generation
  • Third Generation

End-users

  • Schizophrenia
  • Bipolar Disorder
  • Unipolar Depression
  • Dementia
  • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe

Key Players

  • Johnson & Johnson
  • Pfizer
  • Eli Lilly
  • Bristol-Myers Squibb
  • AstraZeneca
  • GSK
  • Allergan

Competitive Landscape

The global major tranquilizers market is highly competitive and major market players include Johnson & Johnson, Pfizer, Eli Lilly, Bristol-Myers Squibb, AstraZeneca, GSK, and Allergan. Rise in psychological disorders is expected to drive the tranquilizer drugs market. Currently the market is facing the production problem because on partial lock down caused due to Covid - 19 pandemic as operation cannot be done in full capacity.

 Major Tranquilizers Market Key Players

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Major Tranquilizers Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Major Tranquilizers Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Major Tranquilizers Market - Supply Chain
  4.5. Global Major Tranquilizers Market Forecast
     4.5.1. Major Tranquilizers Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Major Tranquilizers Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Major Tranquilizers Market Absolute $ Opportunity
5. Global Major Tranquilizers Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Major Tranquilizers Market Size and Volume Forecast by Types
     5.3.1. First Generation
     5.3.2. Second Generation
     5.3.3. Third Generation
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Major Tranquilizers Market Analysis and Forecast by End Users
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by End Users
     6.2.2. Y-o-Y Growth Projections by End Users
  6.3. Major Tranquilizers Market Size and Volume Forecast by End Users
     6.3.1. Schizophrenia
     6.3.2. Bipolar Disorder
     6.3.3. Unipolar Depression
     6.3.4. Dementia
     6.3.5. Others
  6.4. Absolute $ Opportunity Assessment by End Users
  6.5. Market Attractiveness/Growth Potential Analysis by End Users
7. Global Major Tranquilizers Market Analysis and Forecast by Region
  7.1. Market Trends
  7.2. Introduction
     7.2.1. Basis Point Share (BPS) Analysis by Region
     7.2.2. Y-o-Y Growth Projections by Region
  7.3. Major Tranquilizers Market Size and Volume Forecast by Region
     7.3.1. North America
     7.3.2. Latin America
     7.3.3. Europe
     7.3.4. Asia Pacific
     7.3.5. Middle East and Africa (MEA)
  7.4. Absolute $ Opportunity Assessment by Region
  7.5. Market Attractiveness/Growth Potential Analysis by Region
  7.6. Global Major Tranquilizers Demand Share Forecast, 2019-2026
8. North America Major Tranquilizers Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
  8.2. North America Major Tranquilizers Market Size and Volume Forecast by Country
     8.2.1. U.S.
     8.2.2. Canada
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. North America Major Tranquilizers Market Size and Volume Forecast by Types
     8.4.1. First Generation
     8.4.2. Second Generation
     8.4.3. Third Generation
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. North America Major Tranquilizers Market Size and Volume Forecast by End Users
     8.7.1. Schizophrenia
     8.7.2. Bipolar Disorder
     8.7.3. Unipolar Depression
     8.7.4. Dementia
     8.7.5. Others
  8.8. Basis Point Share (BPS) Analysis by End Users
  8.9. Y-o-Y Growth Projections by End Users
  8.10. Market Attractiveness/Growth Potential Analysis
     8.10.1. By Country
     8.10.2. By Product Type
     8.10.3. By Application
  8.11. North America Major Tranquilizers Demand Share Forecast, 2019-2026
9. Latin America Major Tranquilizers Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Latin America Average Pricing Analysis
  9.2. Latin America Major Tranquilizers Market Size and Volume Forecast by Country
      9.2.1. Brazil
      9.2.2. Mexico
      9.2.3. Rest of Latin America
   9.3. Absolute $ Opportunity Assessment by Country
  9.4. Latin America Major Tranquilizers Market Size and Volume Forecast by Types
     9.4.1. First Generation
     9.4.2. Second Generation
     9.4.3. Third Generation
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Latin America Major Tranquilizers Market Size and Volume Forecast by End Users
     9.7.1. Schizophrenia
     9.7.2. Bipolar Disorder
     9.7.3. Unipolar Depression
     9.7.4. Dementia
     9.7.5. Others
  9.8. Basis Point Share (BPS) Analysis by End Users
  9.9. Y-o-Y Growth Projections by End Users
  9.10. Market Attractiveness/Growth Potential Analysis
     9.10.1. By Country
     9.10.2. By Product Type
     9.10.3. By Application
  9.11. Latin America Major Tranquilizers Demand Share Forecast, 2019-2026
10. Europe Major Tranquilizers Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Europe Average Pricing Analysis
  10.2. Europe Major Tranquilizers Market Size and Volume Forecast by Country
     10.2.1. Germany
     10.2.2. France
     10.2.3. Italy
     10.2.4. U.K.
     10.2.5. Spain
     10.2.6. Russia
     10.2.7. Rest of Europe
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Europe Major Tranquilizers Market Size and Volume Forecast by Types
     10.4.1. First Generation
     10.4.2. Second Generation
     10.4.3. Third Generation
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Europe Major Tranquilizers Market Size and Volume Forecast by End Users
     10.7.1. Schizophrenia
     10.7.2. Bipolar Disorder
     10.7.3. Unipolar Depression
     10.7.4. Dementia
     10.7.5. Others
  10.8. Basis Point Share (BPS) Analysis by End Users
  10.9. Y-o-Y Growth Projections by End Users
  10.10. Market Attractiveness/Growth Potential Analysis
     10.10.1. By Country
     10.10.2. By Product Type
     10.10.3. By Application
  10.11. Europe Major Tranquilizers Demand Share Forecast, 2019-2026
11. Asia Pacific Major Tranquilizers Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Asia Pacific Average Pricing Analysis
  11.2. Asia Pacific Major Tranquilizers Market Size and Volume Forecast by Country
     11.2.1. China
     11.2.2. Japan
     11.2.3. South Korea
     11.2.4. India
     11.2.5. Australia
     11.2.6. Rest of Asia Pacific (APAC)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Asia Pacific Major Tranquilizers Market Size and Volume Forecast by Types
     11.4.1. First Generation
     11.4.2. Second Generation
     11.4.3. Third Generation
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Asia Pacific Major Tranquilizers Market Size and Volume Forecast by End Users
     11.7.1. Schizophrenia
     11.7.2. Bipolar Disorder
     11.7.3. Unipolar Depression
     11.7.4. Dementia
     11.7.5. Others
  11.8. Basis Point Share (BPS) Analysis by End Users
  11.9. Y-o-Y Growth Projections by End Users
  11.10. Market Attractiveness/Growth Potential Analysis
     11.10.1. By Country
     11.10.2. By Product Type
     11.10.3. By Application
  11.11. Asia Pacific Major Tranquilizers Demand Share Forecast, 2019-2026
12. Middle East & Africa Major Tranquilizers Market Analysis and Forecast
  12.1. Introduction
     12.1.1. Basis Point Share (BPS) Analysis by Country
     12.1.2. Y-o-Y Growth Projections by Country
     12.1.3. Middle East & Africa Average Pricing Analysis
  12.2. Middle East & Africa Major Tranquilizers Market Size and Volume Forecast by Country
     12.2.1. Saudi Arabia
     12.2.2. South Africa
     12.2.3. UAE
     12.2.4. Rest of Middle East & Africa (MEA)
  12.3. Absolute $ Opportunity Assessment by Country
  12.4. Middle East & Africa Major Tranquilizers Market Size and Volume Forecast by Types
     12.4.1. First Generation
     12.4.2. Second Generation
     12.4.3. Third Generation
  12.5. Basis Point Share (BPS) Analysis by Types
  12.6. Y-o-Y Growth Projections by Types
  12.7. Middle East & Africa Major Tranquilizers Market Size and Volume Forecast by End Users
     12.7.1. Schizophrenia
     12.7.2. Bipolar Disorder
     12.7.3. Unipolar Depression
     12.7.4. Dementia
     12.7.5. Others
  12.8. Basis Point Share (BPS) Analysis by End Users
  12.9. Y-o-Y Growth Projections by End Users
  12.10. Market Attractiveness/Growth Potential Analysis
     12.10.1. By Country
     12.10.2. By Product Type
     12.10.3. By Application
  12.11. Middle East & Africa Major Tranquilizers Demand Share Forecast, 2019-2026
13. Competition Landscape
  13.1. Global Major Tranquilizers Market: Market Share Analysis
  13.2. Major Tranquilizers Distributors and Customers
  13.3. Major Tranquilizers Market: Competitive Dashboard
  13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     13.4.1. Johnson & Johnson
     13.4.2. Pfizer
     13.4.3. Eli Lilly
     13.4.4. Bristol-Myers Squibb
     13.4.5. AstraZeneca
     13.4.6. GSK
     13.4.7. Allergan

Methodology

Our Clients

Microsoft
Dassault Aviation
The John Holland Group
sinopec
General Mills
FedEx Logistics
Deloitte
Pfizer